Physician profile
Naheed Sultana
NPI 1679580948
$3,503.85
in general payments reported to CMS, 2019-2025
20 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,027 · 2020: $245 · 2021: $468 · 2022: $511 · 2023: $270 · 2024: $459 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $947.89 | 2019-2025 | Fasenra, Farxiga, Airsupra |
| Abbott Laboratories | $392.94 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $367.83 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $336.33 | 2019 | |
| Abbvie INC. | $311.14 | 2021-2025 | |
| Lilly USA, LLC | $185.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $155.59 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.72 | 2019-2021 | |
| Dexcom, INC. | $117.19 | 2021 | |
| Merck Sharp & Dohme LLC | $106.27 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.55 | 2022-2024 | |
| Exact Sciences Corporation | $64.18 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $61.22 | 2023-2025 | |
| Shield Therapeutics INC | $53.87 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $52.07 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $39.87 | 2019 | |
| Amgen INC. | $34.81 | 2025 | Otezla, Repatha |
| Corcept Therapeutics | $26.40 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $17.83 | 2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $17.24 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naheed Sultana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.